Loading...
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in S...
Na minha lista:
| Udgivet i: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5228666/ https://ncbi.nlm.nih.gov/pubmed/28072706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005702 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|